

73999/95804

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

In re Application of: Jonathan W. Nyce : Appl.Ref.No: EPI-072
Serial No: 09/093,972 : Group Art Unit: 1632
Filed: June 9, 1998 : Examiner: J. LeGuyader

For: **COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
& TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH
BRONCHOCONSTRICTION, ALLERGY(IES) & INFLAMMATION**

DECLARATION UNDER 37 CFR 1.821(f)

Assistant Commissioner for Patents
Washington D C 20231


Sir/Madam:

I, Viviana Amzel, hereby state that the content of the paper and computer readable copies of the sequence listing submitted herewith, in accordance with 37 CFR 1.821(c) and (e), respectively, include no significant new matter and are, to the best of applicants' knowledge, substantially the same as the sequences submitted with the application as filed. Thus, applicants have fully met the requirements of 37 CFR 1.821 through 1.825 for patent applications containing nucleotide sequence and/or amino acid sequence disclosures.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like, so made, are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,
Arter & Hadden

11/15/99
Date


Viviana Amzel, Ph. D.
Reg. No. 30,930
Attorney for Applicants

Citicorp Center
725 S. Figueroa Street
Los Angeles, California 90071
213-430-3520 Direct Ph.
213-617-9255 Fax

I hereby certify that this paper or fee is being deposited with the United States Postal Service "First Class Mail Post Office to Addressee" service under 37 CFR 1.8 on the date indicated above and is addressed to the Commission of Patents and Trademarks, Washington D C 20231, on November 15, 1999, by Mary Helen Lopez.


SIGNATURE